Celularity retains former President Dr. Pecora as consultant and advisory co-chair

Celularity Inc

Dr. Pecora resigned as President effective Aug 31, 2022; consulting agreement signed Sept 21, 2022.
Consulting fee: $10,000/month for six-month term, automatically renews for one additional six-month term.
Separate scientific/clinical advisor agreement effective Sept 1, 2022: $10,000/month plus $125,000 in RSUs vesting over four years.
Advisor agreement has a one-year term and may be renewed annually by mutual agreement.
No other executive changes disclosed; Pecora remains involved in clinical development and advisory board.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Andrew L. Pecora

President

CELU · Celularity Inc

Effective: 2022-08-31
Filed: September 23, 2022, 7:59 PM ET

As previously disclosed in the Current Report on Form 8-K filed by Celularity Inc, or Celularity, with the Securities and Exchange Commission, or the SEC, on July 20, 2022, Andrew L. Pecora, M.D., F.A.C.P., resigned as Celularity’s President effective as of August 31, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew L. Pecora resigned as President at Celularity Inc.

Action: resigned
Role: President

Exact text from the filing

As previously disclosed in the Current Report on Form 8-K filed by Celularity Inc, or Celularity, with the Securities and Exchange Commission, or the SEC, on July 20, 2022, Andrew L. Pecora, M.D., F.A.C.P., resigned as Celularity’s President effective as of August 31, 2022.

View on SEC.gov

Celularity Inc filing history →

Source: SEC EDGAR

accession 0001193125-22-250130

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.